What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Johan Hansson focuses on Melanoma, Genetics, Cancer research, Internal medicine and Molecular biology.
The study incorporates disciplines such as Mutation, Gene, Immunology, Pathology and CD14 in addition to Melanoma.
Johan Hansson has included themes like Carcinogenesis, Cancer, Cyclin D1 and Exon in his Cancer research study.
The Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology.
His work investigates the relationship between Surgery and topics such as Trametinib that intersect with problems in Phases of clinical research and Hazard ratio.
His Molecular biology study incorporates themes from Cell culture, Cytotoxic T cell, T cell, Antigen-presenting cell and Lymphokine-activated killer cell.
His most cited work include:
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma (1049 citations)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (771 citations)
- Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. (504 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Melanoma, Cancer research, Internal medicine, Oncology and Genetics.
As a member of one scientific family, Johan Hansson mostly works in the field of Melanoma, focusing on Immunology and, on occasion, Cytotoxic T cell.
His research investigates the connection with Cancer research and areas like Cell culture which intersect with concerns in Molecular biology.
The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine.
His Oncology research is multidisciplinary, incorporating perspectives in Survival analysis and Chemotherapy, Phases of clinical research.
His studies deal with areas such as Odds ratio and Proportional hazards model as well as Hazard ratio.
He most often published in these fields:
- Melanoma (53.98%)
- Cancer research (31.84%)
- Internal medicine (28.86%)
What were the highlights of his more recent work (between 2017-2021)?
- Melanoma (53.98%)
- Cancer research (31.84%)
- Internal medicine (28.86%)
In recent papers he was focusing on the following fields of study:
Johan Hansson mostly deals with Melanoma, Cancer research, Internal medicine, Oncology and Nivolumab.
His research in Melanoma intersects with topics in Cancer, Targeted therapy, Immunotherapy, Progression-free survival and Peripheral blood mononuclear cell.
His research integrates issues of Genetic heterogeneity and Crizotinib in his study of Cancer research.
Internal medicine and Cutaneous melanoma are frequently intertwined in his study.
His Oncology research incorporates themes from Germline mutation, Pancreatic cancer, Phases of clinical research, Genetic testing and Receiver operating characteristic.
He usually deals with Nivolumab and limits it to topics linked to Pembrolizumab and Myeloid-derived Suppressor Cell, Chromatin remodeling and Metastasis.
Between 2017 and 2021, his most popular works were:
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. (109 citations)
- Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. (66 citations)
- Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. (66 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Johan Hansson mostly deals with Melanoma, Cancer research, Internal medicine, Oncology and Targeted therapy.
His study in the field of Cutaneous melanoma also crosses realms of Afatinib.
His Cutaneous melanoma study combines topics from a wide range of disciplines, such as Odds ratio, Progression-free survival, Microvesicles, microRNA and Hazard ratio.
His work carried out in the field of Cancer research brings together such families of science as Downregulation and upregulation, Immune system, Intratumoral Genetic Heterogeneity, Tumor progression and Regulation of gene expression.
His Oncology study integrates concerns from other disciplines, such as Symptom severity, Quality of life and Phases of clinical research.
His Targeted therapy research integrates issues from Cell cycle, Crizotinib and Insulin-like growth factor 1 receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
